Pharmaceutical packaging units and methods for concomitant administration of radiotracers

A pharmaceutical packaging unit, comprising:

• a first radiotracer;
• and
• a second radiotracer,
• wherein the first radiotracer and the second radiotracer have different pharmacokinetics.

A pharmaceutical packaging unit comprising:

• a first radiotracer;
• and
• a second radiotracer,
• wherein the first radiotracer and the second radiotracer have different binding affinities for the dopamine transporter (DAT) and different pharmacokinetics.

A method of determining if a subject not manifesting a clinical symptom of a dopaminergic disorder is afflicted with the dopaminergic disorder, comprising:

• administering a first radiotracer;
• waiting for a first time interval;
• administering a second radiotracer;
• waiting for a second time interval,
• the first radiotracer and the second radiotracer having different binding affinities for the dopamine transporter (DAT) and different pharmacokinetics;
• acquiring counts from the first radiotracer and the second radiotracer, bound to DAT in a region of interest (ROI) of the body of the subject;
• measuring a number, density, and/or pattern of counts acquired;
• and
• comparing the number, density, and/or pattern of counts acquired from the ROI of the subject with the number, density, and/or pattern of counts obtained from an unafflicted, age-matched control subject,
• the patient being afflicted with a dopaminergic movement disorder if the number, density and/or pattern of counts detected in the ROI is reduced relative to the counts, density, and/or pattern of counts obtained from the ROI the unafflicted, age-match control subject.

A method of determining if a subject not manifesting a clinical symptom of a dopaminergic disorder is afflicted with the dopaminergic disorder, comprising:

• administering a second radiotracer;
• waiting for a first time interval;
• administering a first radiotracer;
• waiting for a second time interval,
• the first radiotracer and the second radiotracer have different binding affinities for dopamine transporter (DAT) and different pharmacokinetics;
• acquiring counts from the first radiotracer and the second radiotracer, bound to DAT in a region of interest (ROI) of the body of the subject;
• measuring a number, density, and/or pattern of counts acquired;
• and comparing the number, density, and/or pattern of counts acquired from the ROI of the subject with the number, density, and/or pattern of counts obtained from an unafflicted, age-matched control subject,
• the patient being afflicted with a dopaminergic movement disorder if the number, density and/or pattern of counts detected in the ROI is reduced relative to the counts, density, and/or pattern of counts obtained from the ROI the unafflicted, age-match control subject.